NO.1 PHARMACY(SH:600833)2017-10-30 16:00Financial Performance - Net profit attributable to shareholders was CNY 36,926,722.07, representing a decline of 11.20% year-on-year[5]. - Operating revenue for the period was CNY 1,176,934,954.82, an increase of 1.94% compared to the same period last year[5]. - The company reported a decrease in investment income by 32.17% to CNY 4,831,132.12 compared to the same period last year[8]. - Total operating revenue for Q3 2017 was CNY 357,930,320.80, a slight increase of 1.9% compared to CNY 351,592,790.22 in Q3 2016[19]. - Net profit for Q3 2017 decreased to CNY 12,398,870.78, down 29.5% from CNY 17,471,371.06 in Q3 2016[19]. - The company reported a total profit of CNY 15,008,712.91 for Q3 2017, a decrease of 29.7% compared to CNY 21,348,662.51 in Q3 2016[19]. - The company’s total operating revenue for the first nine months of 2017 was CNY 1,176,934,954.82, an increase of 1.9% from CNY 1,154,483,236.86 in the same period of 2016[19]. - The net profit for the first nine months of 2017 was CNY 36,926,722.07, a decrease of 11.2% from CNY 41,583,966.97 in the same period of 2016[19]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,162,515,997.83, a decrease of 1.92% compared to the end of the previous year[5]. - Total current assets increased to CNY 675,823,375.11 from CNY 669,837,559.84, a growth of approximately 0.13%[13]. - Total non-current assets decreased to CNY 486,692,622.72 from CNY 515,449,564.10, a decline of about 5.6%[13]. - Total liabilities decreased to CNY 424,190,865.08 from CNY 449,291,013.61, a reduction of approximately 5.6%[14]. - The company’s total current liabilities decreased to CNY 334,469,285.65 from CNY 352,957,941.20, a decline of approximately 5.3%[14]. Cash Flow - Net cash flow from operating activities increased by 32.20% to CNY 66,973,642.15 compared to the previous year[5]. - The total cash inflow from operating activities for the first nine months of 2017 was CNY 1,253,961,625.20, an increase of 2.5% compared to CNY 1,223,728,033.94 in the same period last year[22]. - The net cash flow from operating activities was CNY 66,973,642.15, up from CNY 50,661,363.32, representing a year-over-year increase of 32.2%[22]. - The cash inflow from investment activities was CNY 4,946,825.36, down 30.8% from CNY 7,162,358.84 in the previous year[22]. - The net cash flow from investment activities was CNY 3,329,379.63, a decrease of 40% compared to CNY 5,545,778.93 last year[22]. - The cash outflow for financing activities was CNY 15,614,843.86, compared to CNY 13,383,564.76 in the same period last year, indicating an increase of 16.5%[23]. - The net increase in cash and cash equivalents was CNY 54,688,177.92, compared to CNY 42,823,577.49 in the previous year, reflecting a growth of 27.7%[22]. - The ending balance of cash and cash equivalents was CNY 282,236,542.72, up from CNY 242,388,244.52, marking an increase of 16.5% year-over-year[22]. Shareholder Information - The total number of shareholders at the end of the reporting period was 24,224[7]. Other Financial Metrics - The weighted average return on equity decreased by 0.44 percentage points to 5.06%[5]. - Basic earnings per share for Q3 2017 were CNY 0.0556, down from CNY 0.0783 in Q3 2016[19]. - Other comprehensive income after tax for Q3 2017 was CNY 2,808,184.01, a significant recovery from a loss of CNY 18,654,451.82 in Q3 2016[19]. - The company’s total comprehensive income for Q3 2017 was CNY 15,207,054.79, compared to a loss of CNY 1,183,080.76 in Q3 2016[19].